Spruce Biosciences, Inc.
SPRBNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $109.76M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $38.06$148.88
- Volume (live)
- -
- Avg. volume (3M)
- 87.08K
Spruce Biosciences (SPRB) Stock Price & Financial Analysis
Spruce Biosciences Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $43.34 - $46.10 |
|---|---|
| 52-Week High | $148.88 |
| 52-Week Low | $38.06 |
| Open | $45.80 |
| Volume (last close) | 73.79K |
| Average Volume (3M) | 87.08K |
| 50-Day MA | $50.87 |
|---|---|
| 200-Day MA | $57.12 |
| 1-Year Change | −64.59% |
| Market Cap | 109.76M |
|---|---|
| Shares Outstanding | 2.43M |
| Price to Book (P/B) | 1.31 |
| EV/EBITDA | -0.48 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Spruce Biosciences at a Glance
As of the Oct 23, 2026 close, Spruce Biosciences (SPRB) has a market capitalization of $109.76M. Revenue fell 100.0% year over year.
As of its latest reported balance sheet, it holds $96.30M in cash and securities against $8.01M of debt, a net cash position of $88.29M.
Spruce Biosciences does not currently pay a dividend.
The share price is down 64.6% over the past year. At $45.15 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $38.06 to $148.88, below its 200-day moving average of $57.12.
Based on 5 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $154.60, 242.4% above the Oct 23, 2026 close.
Frequently Asked Questions About Spruce Biosciences
What is the current stock price for SPRB?
As of the Oct 23, 2026 close, SPRB stock trades at $45.15. The 52-week range is $38.06–$148.88, with a day range of $43.34–$46.10.
What is the P/E ratio for SPRB?
The P/E ratio (Price-to-Earnings) for SPRB is shown in the Key Statistics section. This valuation metric helps compare Spruce Biosciences, Inc. to industry peers.
Does SPRB pay dividends?
Spruce Biosciences does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for SPRB?
Based on ratings from 5 professional analysts over the last 90 days, the consensus for SPRB is Buy. The average 12-month price target is $154.60, a 242.4% upside from the Oct 23, 2026 close of $45.15.
What is the market cap of SPRB?
As of the Oct 23, 2026 close, Spruce Biosciences's market capitalization is $109.8M, classifying it as a micro-cap company. Spruce Biosciences operates in the Healthcare sector within the Biotechnology industry.